SynCore Biotechnology Co.,Ltd (TPEX:4192)
Taiwan · Delayed Price · Currency is TWD 19.95
-0.05 (-0.25%)
Aug 26, 2026, 12:14 PM CST
TPEX:4192 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 26.24 | 27.04 | 23.34 | 20.2 | 15.86 | 6.94 | |
Revenue Growth | 4.63% | 15.88% | 15.55% | 27.36% | 128.52% | -47.97% |
Cost of Revenue | 4.88 | 5.96 | 10.45 | 19.68 | 6.77 | 3.97 |
Gross Profit | 21.36 | 21.09 | 12.89 | 0.52 | 9.09 | 2.97 |
Selling, General & Admin | 45.38 | 43.77 | 42.33 | 42.09 | 43.33 | 38.62 |
Research & Development | 24.73 | 24.51 | 28.31 | 3.94 | 157.23 | 422.97 |
Operating Expenses | 70.2 | 68.28 | 70.64 | 46.02 | 200.56 | 461.59 |
Operating Income | -48.84 | -47.2 | -57.76 | -45.5 | -191.47 | -458.62 |
Interest Expense | -0.2 | -0.17 | -0.3 | -0.78 | -2.27 | -2.04 |
Interest & Investment Income | 1.69 | 1.92 | 2.31 | 2.37 | 1.42 | 1.03 |
Currency Exchange Gain (Loss) | -0.44 | -0.44 | 1.16 | 5.65 | -2.99 | -4.17 |
Other Non Operating Income (Expenses) | 0.83 | 0.02 | 0.01 | 0.09 | 6.77 | 5.2 |
EBT Excluding Unusual Items | -46.96 | -45.87 | -54.58 | -38.18 | -188.54 | -458.6 |
Gain (Loss) on Sale of Investments | 0.12 | 0.12 | 0.3 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | -0.13 | - |
Other Unusual Items | - | - | - | 0.01 | - | - |
Pretax Income | -46.85 | -45.76 | -54.28 | -38.17 | -188.67 | -458.6 |
Net Income | -46.85 | -45.76 | -54.28 | -38.17 | -188.67 | -458.6 |
Net Income to Common | -46.85 | -45.76 | -54.28 | -38.17 | -188.67 | -458.6 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 35 | 35 | 35 | 32 | 31 | 30 |
Shares Outstanding (Diluted) | 35 | 35 | 35 | 32 | 31 | 30 |
Shares Change | 0.07% | - | 9.69% | 4.27% | 1.26% | 9.16% |
EPS (Basic) | -1.33 | -1.30 | -1.54 | -1.19 | -6.14 | -15.10 |
EPS (Diluted) | -1.33 | -1.30 | -1.54 | -1.19 | -6.14 | -15.10 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -32.49 | -38.57 | -49.45 | -82.79 | -209.75 | -230.15 |
Free Cash Flow Per Share | -0.92 | -1.10 | -1.41 | -2.58 | -6.82 | -7.58 |
Gross Margin | 81.41% | 77.98% | 55.22% | 2.58% | 57.30% | 42.79% |
Operating Margin | -186.15% | -174.52% | -247.49% | -225.30% | -1207.50% | -6609.30% |
Profit Margin | -178.54% | -169.19% | -232.60% | -189.01% | -1189.80% | -6608.98% |
Free Cash Flow Margin | -123.83% | -142.61% | -211.89% | -409.92% | -1322.74% | -3316.73% |
EBITDA | -41.08 | -39.37 | -49.5 | -36.99 | -165.71 | -454.51 |
EBITDA Margin | -156.57% | -145.60% | -212.10% | -183.16% | - | - |
D&A For EBITDA | 7.76 | 7.82 | 8.26 | 8.51 | 25.77 | 4.11 |
EBIT | -48.84 | -47.2 | -57.76 | -45.5 | -191.47 | -458.62 |
EBIT Margin | -186.15% | -174.52% | -247.49% | -225.30% | - | - |